OncBioMune Pharmaceuticals, Inc (62)
Browse by Contract Category
Contracts
-
Offer Letter between the Company and Faith Zaslavsky, dated December 5, 2022
(Filed With SEC on December 9, 2022)
-
Form of Security Agreement
(Filed With SEC on December 1, 2022)
-
Placement Agency Agreement by and between the Company and Joseph Gunnar & Co
(Filed With SEC on December 1, 2022)
-
Consulting Agreement between OncBioMune Pharmaceuticals, Inc. and Andrew Kucharchuk effective January 1, 2021
(Filed With SEC on January 13, 2022)
-
Form of Securities Purchase Agreement
(Filed With SEC on December 1, 2022)
-
Form of 10% Original Issue Discount Senior Secured Convertible Debentures (Exchanged Debentures)
(Filed With SEC on December 1, 2022)
-
Form of Common Stock Purchase Warrant
(Filed With SEC on December 1, 2022)
-
Form of 10% Original Issue Discount Senior Secured Convertible Debentures
(Filed With SEC on December 1, 2022)
-
Form of Demand Note
(Filed With SEC on September 16, 2022)
-
Form of Securities Purchase Agreement for April 2022
(Filed With SEC on May 23, 2022)
-
Form of Common Stock Purchase Warrant for April 2022
(Filed With SEC on May 23, 2022)
-
Form of Convertible Promissory Note for April 2022
(Filed With SEC on May 23, 2022)
-
Form of Common Stock Purchase Warrant 2
(Filed With SEC on February 3, 2022)
-
Engagement Letter, by and between Carter, Terry & Company and Theralink Technologies, Inc., dated December 15, 2021, as amended
(Filed With SEC on February 3, 2022)
-
Form of Securities Purchase Agreement
(Filed With SEC on February 3, 2022)
-
Securities Purchase Agreement, dated November 1, 2021
(Filed With SEC on November 5, 2021)
-
Form of Common Stock Purchase Warrant, issued November 1, 2021
(Filed With SEC on November 5, 2021)
-
Form of Convertible Promissory Note, dated November 1, 2021
(Filed With SEC on November 5, 2021)
-
Employment Agreement, dated June 5, 2020 by and between Jeffrey Busch and OncBioMune Pharmaceuticals, Inc
(Filed With SEC on September 27, 2021)
-
Employment Agreement, dated June 5, 2020 by and between Dr. Michael Ruxin and OncBioMune Pharmaceuticals, Inc
(Filed With SEC on September 27, 2021)
-
Securities Purchase Agreement, dated July 30, 2021
(Filed With SEC on August 6, 2021)
-
Common Stock Purchase Warrant, issued July 30, 2021
(Filed With SEC on August 6, 2021)
-
Security Agreement, dated May 12, 2021
(Filed With SEC on May 19, 2021)
-
Securities Purchase Agreement, dated May 12, 2021
(Filed With SEC on May 19, 2021)
-
Common Stock Purchase Warrant, issued May 12, 2021
(Filed With SEC on May 19, 2021)
-
Convertible Secured Promissory Note, dated May 12, 2021
(Filed With SEC on May 19, 2021)
-
Form of Registration Rights Agreement
(Filed With SEC on April 20, 2021)
-
Form of Subscription Agreement
(Filed With SEC on April 20, 2021)
-
Securities Purchase Agreement, dated September 16, 2020, by and among OncBioMune Pharmaceuticals, Inc. and the Investor
(Filed With SEC on September 22, 2020)
-
Consulting Agreement between OncBioMune Pharmaceuticals, Inc. and Andrew Kucharchuk dated June 5, 2020
(Filed With SEC on June 11, 2020)
-
Separation Agreement and General Release of Claims between OncBioMune Pharmaceuticals, Inc. and Andrew Kucharchuk dated June 5, 2020
(Filed With SEC on June 11, 2020)
-
Securities Purchase Agreement, dated June 5, 2020, by and among OncBioMune Pharmaceuticals, Inc. Cavalry Fund I LP and Lincoln Park Capital Fund, LLC
(Filed With SEC on June 11, 2020)
-
Exchange Agreement, dated June 5, 2020, by and between OncBioMune Pharmaceuticals, Inc. and Jonathan F. Head, Ph.D
(Filed With SEC on June 11, 2020)
-
Exchange Agreement, dated June 5, 2020, by and among OncBioMune Pharmaceuticals, Inc. and the Investors named therein
(Filed With SEC on June 11, 2020)
-
Exchange Agreement, dated June 5, 2020, by and among OncBioMune Pharmaceuticals, Inc. and the Investors named therein
(Filed With SEC on June 11, 2020)
-
Exchange Warrant, dated June 5, 2020
(Filed With SEC on June 11, 2020)
-
Form of Warrant
(Filed With SEC on June 11, 2020)
-
Asset Purchase Agreement, dated May 12, 2020, between OncBioMune Pharmaceuticals, Inc. and Avant Diagnostics, Inc
(Filed With SEC on May 13, 2020)
-
Description of Capital Stock
(Filed With SEC on March 25, 2020)
-
Securities Purchase Agreement dated September 25, 2019
(Filed With SEC on November 19, 2019)
-
Warrant dated September 25, 2019
(Filed With SEC on November 19, 2019)
-
Note dated September 25, 2019
(Filed With SEC on November 19, 2019)
-
Securities Purchase Agreement
(Filed With SEC on August 6, 2019)
-
Form of Warrant
(Filed With SEC on August 6, 2019)
-
Form of Note
(Filed With SEC on August 6, 2019)
-
Form of Note
(Filed With SEC on July 18, 2019)
-
Form of Securities Purchase Agreement
(Filed With SEC on July 18, 2019)
-
Form of Warrant
(Filed With SEC on July 18, 2019)
-
Form of Securities Purchase Agreement
(Filed With SEC on May 2, 2019)
-
Form of Warrant
(Filed With SEC on May 2, 2019)
-
Form of Note
(Filed With SEC on May 2, 2019)
-
Common Stock Purchase Warrant issued March 25, 2019 to Cavalry Fund I LP
(Filed With SEC on April 1, 2019)
-
Securities Purchase Agreement between OncBioMune Pharmaceuticals, Inc. and Cavalry Fund I LP, dated March 25, 2019
(Filed With SEC on April 1, 2019)
-
Senior Convertible Note issued March 25, 2019 to Cavalry Fund I LP
(Filed With SEC on April 1, 2019)
-
Employment Agreement effective as of December 26, 2018 between OncBioMune Pharmaceuticals, Inc. and Brian Barnett, MD
(Filed With SEC on April 1, 2019)
-
Shareholders Agreement among OncBioMune Pharmaceuticals, Inc., Jonathan F. Head, Ph.D., Andrew A. Kucharchuk, Manuel Cosme Odabachian and Carlos Fernando Alaman Volnie dated March...
(Filed With SEC on February 21, 2019)
-
Irrevocable Trust Agreement Number F/2868 entered into among Manuel Cosme Odabachian, Carlos Fernando Alaman Volnie and OncBioMune Pharmaceuticals, Inc. as beneficiaries and Banco...
(Filed With SEC on February 21, 2019)
-
Contribution Agreement to the Property of Trust F/2868 entered into among Manuel Cosme Odabachian, Carlos Fernando Alaman Volnie and OncBioMune Pharmaceuticals, Inc. dated March...
(Filed With SEC on February 21, 2019)
-
Convertible Redeemable Note, dated as of January 18, 2019
(Filed With SEC on February 4, 2019)
-
Securities Purchase Agreement, dated as of January 18, 2019, by and between OncBioMune Pharmaceuticals, Inc. and Cerberus Finance Group Ltd
(Filed With SEC on February 4, 2019)
-
Securities Purchase Agreement, dated as of January 18, 2019, by and between OncBioMune Pharmaceuticals, Inc. and LG Capital Funding LLC
(Filed With SEC on January 29, 2019)
-
Convertible Redeemable Note, dated as of January 18, 2019
(Filed With SEC on January 29, 2019)